Type:
The Nucleic Acid Therapeutics CDMO market can be categorized by type into RNA-based therapeutics, DNA-based therapeutics, and others. RNA-based therapeutics segment is expected to dominate the market, owing to the increasing research and development activities in RNA-based drug discovery and the potential of RNA therapies in treating various diseases.
Service:
The Nucleic Acid Therapeutics CDMO market offers services such as process development & optimization and manufacturing services. The process development & optimization segment is anticipated to witness significant growth, as it plays a crucial role in the early stages of drug development and ensures the efficiency and effectiveness of the manufacturing process.
End-user:
The Nucleic Acid Therapeutics CDMO market caters to end-users including pharmaceutical companies, biotech companies, and research institutes. The pharmaceutical companies segment is projected to hold a major share in the market, driven by the increasing collaborations between pharmaceutical companies and CDMOs to develop nucleic acid-based therapies.
Application:
In terms of application, the Nucleic Acid Therapeutics CDMO market covers various areas such as oncology, rare diseases, infectious diseases, and others. The oncology segment is expected to witness steady growth, owing to the rising incidence of cancer globally and the increasing adoption of nucleic acid therapeutics in cancer treatment.